Zotepine

Study	Type of data	Exposure measurement	Outcome assessment	Adjustment
Habermann (Control exposed to FGA), 2013	prospective cohort	Data ascertainment was performed using 2 structured questionnaires at (1) the first contact and (2) 8 weeks after the estimated date of birth. A detailed history of drug use is recorded at the first contact.	Follow up is especially focused on congenital anomalies and postnatal disorders. For this purpose, during interview, the hospital discharge summaries are asked for.	No adjustment for this exposed group.
Habermann (Control unexposed, disease free), 2013	prospective cohort	Data ascertainment was performed using 2 structured questionnaires at (1) the first contact and (2) 8 weeks after the estimated date of birth. A detailed history of drug use is recorded at the first contact.	Follow up is especially focused on congenital anomalies and postnatal disorders. For this purpose, during interview, the hospital discharge summaries are asked for.	No adjustment for this exposed group.